TITLE

α1-Adrenoceptor Subtype Selectivity and Lower Urinary Tract Symptoms

AUTHOR(S)
Schwinn, Debra A.; Price, David T.; Narayan, Perinchery
PUB. DATE
November 2004
SOURCE
Mayo Clinic Proceedings;Nov2004, Vol. 79 Issue 11, p1423
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Benign prostatic hyperplasia is a common cause of urinary flow obstruction in aging men and may lead to lower urinary tract symptoms (LUTS). Benign prostatic hyperplasia has 2 physiological components: a static component related to Increased prostate size and a dynamic component related to Increased prostate smooth muscle tone. α1-Adrenoceptors (αARS) maintain prostate smooth muscle tone; hence, α1-antagonists (blockers) relax prostate smooth muscle and decrease urethral resistance, ultimately leading to relief of LUTS. This review focuses on α1AR subtypes and their location in lower urinary tract tissues involved in LUTS (prostate, bladder, spinal cord); it also summarizes major clinical trials published to date on the efficacy of α1AR blockers for LUTS. Benefits and adverse effects of clinically available α1AR antagonists are reviewed, followed by recent information on interactions between α1AR subtype antagonists and type 5 phosphodiesterase Inhibitors used for impotence. α1-Adenoceptor antagonists have become the mainstay of therapy for LUTS; knowledge about specific α1AR subtypes should facilitate rational choice of α1AR blocker therapy by clinicians.
ACCESSION #
15032245

 

Related Articles

  • Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Griwan, Mahavir Singh; Karthikeyan, Y. R.; Kumar, Mandeep; Singh, Bikram Jit; Singh, Santosh Kumar // Urology Annals;Jul2014, Vol. 6 Issue 3, p181 

    Introduction: Naftopidil, approved initially in Japan, is an α1d-adrenergic receptor antagonist (α1-blocker) used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). It is different from tamsulosin hydrochloride and silodosin, in that it has a higher...

  • Beta-arrestin-2 is expressed in human prostate smooth muscle and a binding partner of α1A-adrenoceptors. Hennenberg, Martin; Schlenker, Boris; Roosen, Alexander; Strittmatter, Frank; Walther, Sebastian; Stief, Christian; Gratzke, Christian // World Journal of Urology;Apr2011, Vol. 29 Issue 2, p157 

    Purpose: Alpha1A-adrenoceptors are important regulators of prostatic smooth muscle tone and an important target for therapy of lower urinary tract symptoms. The function of heptahelical transmembrane receptors such as adrenoceptors can be regulated by β-arrestin-2, which may bind to receptors...

  • Estimating a population's needs for the treatment of lower urinary tract symptoms in men: what is the extent of unmet need? Treagust, Janette; Morkane, Tony; Speakman, Mark // Journal of Public Health Medicine;Jun2001, Vol. 23 Issue 2, p141 

    Background Prevalence surveys have shown that men aged over 40 commonly experience lower urinary tract symptoms (LUTS). However, such studies cannot be used in isolation to inform health service planning, as not all men are troubled by their symptoms nor would they necessarily benefit from...

  • Benign prostatic hyperplasia: An overview of existing treatment. Dhingra, Neelima; Bhagwat, Deepak // Indian Journal of Pharmacology;Feb2011, Vol. 43 Issue 1, p6 

    Benign prostatic hyperplasia (BPH) is the most common condition in aging men, associated with lower urinary tract symptoms (LUTS). A better understanding of the prostate physiology, function, and pathogenesis has led to the development of promising agents, useful in the management of LUTS in...

  • Metabolic syndrome and benign prostatic hyperplasia: association or coincidence? Rył, Aleksandra; Rotter, Iwona; Miazgowski, Tomasz; Słojewski, Marcin; Dołęgowska, Barbara; Lubkowska, Anna; Laszczyńska, Maria // Diabetology & Metabolic Syndrome;10/26/2015, Vol. 7, p1 

    Background: It has been suggested that individuals with metabolic syndrome (MetS) may be prone to developing benign prostatic hyperplasia (BPH), but the direction of causality remains uncertain. The objective of this cross-sectional study was to evaluate the association between BPH and MetS in...

  • A Review on Various Analytical Methods on Some Alpha Adrenergic Antagonists. Shrivastava, Alankar; Gupta, Vipin B. // Current Pharmaceutical Analysis;Feb2011, Vol. 7 Issue 1, p27 

    Background: Although initially introduced for the management of hypertension, αl-adrenergic-receptor antagonists (αlblockers) have become the standard of care for the medical management of benign prostatic hyperplasia (BPH) related lower urinary tract symptoms (LUTS). Alpha-blockers...

  • A review of medicines used to treat benign prostatic hyperplasia. Coetzer, Ronelle // South African Pharmaceutical Journal;2013, Vol. 80 Issue 4, p23 

    Benign prostatic hyperplasia (BPH) is a common condition that affects ageing men and is often associated with bothersome lower urinary tract symptoms which can affect quality of life. This review will discuss the condition, as well as potential treatment options and products, which should be...

  • Long--Term Therapy of Urinary Tract Infections. Kunin, Calvin M. // Annals of Internal Medicine;Aug75, Vol. 83 Issue 2, p273 

    Editorial. Comments on the long-term therapy of urinary tract infections. Causes of recurrent infections in men; Results of a study on the management of recurrent urinary infections in elderly men; Opinion on how clinicians can take advantage of such findings in caring for patients with the...

  • Tamsulosin: An Update of its Role in the Management of Lower Urinary Tract Symptoms. Lyseng-Williamson, K.A.; Jarvis, B.; Wagstaff, A.J. // Drugs;2002, Vol. 62 Issue 1, p135 

    Tamsulosin is a selective α- and α-adrenoceptor antagonist. These α-receptors are predominant in the prostate, prostatic capsule, prostatic urethra and bladder. The relaxation of prostate and bladder smooth muscles may result in improvement in maximum urine flow (Q) and reduction of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics